← Autonomix Medical, Inc. Common Stock overview

Autonomix Medical, Inc. Common Stock vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Autonomix Medical, Inc. Common Stock (AMIX)

Q3 2026
▲2

Autonomix's patent wins and cash raises drive volatile AMIX surge

  • New patents expand nerve-targeting platform Autonomix won three new US patents: overactive bladder diagnosis/treatment, autonomic nervous system assessment, and nerve-targeting cancer technology. These broaden its nerve-sensing platform into urology and oncology, boosting the long-term potential of its technology and supporting investor optimism.

    Patent wins are a core new driver of AMIX's growth story and stock interest.

  • Warrant deals bring in $7.5 million cash Autonomix raised about $2.6 million in July and $4.9 million in August by getting investors to exercise old warrants early. This cash strengthens the company's finances and funds operations, which reduces the risk of running out of money and supports the stock price.

    These capital raises directly improve AMIX's liquidity and are a major reason for the recent price jump.

  • Preclinical renal denervation data met with sell-off Autonomix reported positive preclinical results for its nerve-sensing platform in renal denervation, but the stock fell 16% that day. The drop shows investors may have already expected good news or worried about the cost of future studies, a reminder that clinical progress can still bring sharp pullbacks.

    This event shows the market's mixed reaction to pipeline news and is a real counterweight to the positive patent and cash stories.

August 2026
▲2

Autonomix's patent wins and cash raises drive volatile AMIX surge

  • New patents expand nerve-targeting platform Autonomix won three new US patents: overactive bladder diagnosis/treatment, autonomic nervous system assessment, and nerve-targeting cancer technology. These broaden its nerve-sensing platform into urology and oncology, boosting the long-term potential of its technology and supporting investor optimism.

    Patent wins are a core new driver of AMIX's growth story and stock interest.

  • Warrant deals bring in $7.5 million cash Autonomix raised about $2.6 million in July and $4.9 million in August by getting investors to exercise old warrants early. This cash strengthens the company's finances and funds operations, which reduces the risk of running out of money and supports the stock price.

    These capital raises directly improve AMIX's liquidity and are a major reason for the recent price jump.

  • Preclinical renal denervation data met with sell-off Autonomix reported positive preclinical results for its nerve-sensing platform in renal denervation, but the stock fell 16% that day. The drop shows investors may have already expected good news or worried about the cost of future studies, a reminder that clinical progress can still bring sharp pullbacks.

    This event shows the market's mixed reaction to pipeline news and is a real counterweight to the positive patent and cash stories.

Latest
▲2

Autonomix's patent wins and cash raises drive volatile AMIX surge

  • New patents expand nerve-targeting platform Autonomix won three new US patents: overactive bladder diagnosis/treatment, autonomic nervous system assessment, and nerve-targeting cancer technology. These broaden its nerve-sensing platform into urology and oncology, boosting the long-term potential of its technology and supporting investor optimism.

    Patent wins are a core new driver of AMIX's growth story and stock interest.

  • Warrant deals bring in $7.5 million cash Autonomix raised about $2.6 million in July and $4.9 million in August by getting investors to exercise old warrants early. This cash strengthens the company's finances and funds operations, which reduces the risk of running out of money and supports the stock price.

    These capital raises directly improve AMIX's liquidity and are a major reason for the recent price jump.

  • Preclinical renal denervation data met with sell-off Autonomix reported positive preclinical results for its nerve-sensing platform in renal denervation, but the stock fell 16% that day. The drop shows investors may have already expected good news or worried about the cost of future studies, a reminder that clinical progress can still bring sharp pullbacks.

    This event shows the market's mixed reaction to pipeline news and is a real counterweight to the positive patent and cash stories.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.